NCT03545191Visual Analogue Scaleinsomniadaridorexantinsomnia-relatedIdorsia Pharmaceuticals Ltd.
…ive of the menopausal transition, enrolled in the phase 3 study NCT03545191.Methods In this randomized, double-blind study, 930 patients wi…
2articles mentioning institutions
2institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT03545191 ×
NCT03545191
This institution is selected. Its supporting articles are shown below.
Articles mentioning NCT03545191
2 articles · page 1 of 1NCT03545191Visual Analogue Scaledaridorexantobstructive sleep apneainsomnia disorderIdorsia Pharmaceuticals LtdOSA
…5 events per hour) at screening from the 3-month Phase 3 trial (NCT03545191). Endpoints assessed at Month (M) 1 and M3 include PSG measured…